Nevertheless, due to its key role in chronic inflammation and heavily influenced by the success of TNFα inhibition in autoimmune conditions such as RA (McKellar et al., 2009), TNFα inhibitors were among the first biologics to be clinically investigated for CVD. The gene discussed is TNF; the disease is rheumatoid arthritis.